Lord Abbett & CO. LLC Acquires New Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Lord Abbett & CO. LLC purchased a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 3,094,457 shares of the biotechnology company's stock, valued at approximately $61,858,000. Lord Abbett & CO. LLC owned about 1.31% of ADMA Biologics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of ADMA. USA Financial Formulas increased its holdings in ADMA Biologics by 8.6% during the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock valued at $136,000 after purchasing an additional 539 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in ADMA Biologics by 7.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company's stock worth $273,000 after purchasing an additional 888 shares during the last quarter. Hollencrest Capital Management bought a new position in shares of ADMA Biologics in the 3rd quarter valued at about $30,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in ADMA Biologics by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company's stock valued at $163,000 after buying an additional 1,509 shares during the period. Finally, Larson Financial Group LLC bought a new position in shares of ADMA Biologics in the 3rd quarter worth $31,000. 75.68% of the stock is owned by institutional investors.

Insider Transactions at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ADMA has been the topic of a number of research analyst reports. Raymond James raised their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, HC Wainwright boosted their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th.

ADMA Biologics Stock Performance

NASDAQ:ADMA traded down $0.08 during mid-day trading on Friday, reaching $18.59. 1,979,915 shares of the company's stock were exchanged, compared to its average volume of 3,583,493. ADMA Biologics, Inc. has a one year low of $3.95 and a one year high of $23.64. The business's fifty day simple moving average is $19.02 and its two-hundred day simple moving average is $16.10. The firm has a market capitalization of $4.39 billion, a PE ratio of 66.39 and a beta of 0.70. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. During the same quarter last year, the business earned $0.01 earnings per share. Analysts anticipate that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.